https://www.selleckchem.com/products/ab928.html
This study aimed to investigate the efficacy and safety of mirabegron for Parkinsonism patients with overactive bladder (OA symptoms in a randomized, placebo-controlled, multicenter study. Inclusion criteria are Parkinsonism with OAB symptoms for 4 weeks or more, OAB symptom score (OABSS) questionnaire scores greater than 2, and OABSS urgency question scores greater than 1. After a 2-week wash-out period, the patients were randomized into placebo and mirabegron groups at visit 2. Visit 3 was performed after 4 weeks of medication. Mirabe
Like
Comment
Share
